Transmitted Drug Resistance (TDR) in HIV-1 presents a risk for the future success and longevity of Highly Active Antiretroviral Therapy (HAART) especially in resource limited settings in which no genotypic testing is conducted prior to treatment initiation and options for treatment and salvage therapy is limited. For HIV-1 subtype C, the most prevalent subtype in sub-Saharan Africa, there is limited information available on the prevalence of TDR and the persistence of TDR associated mutations, aspects which are integral in informing decisions on future treatment strategies for HIV-1. We investigated the prevalence and persistence of low frequency TDR associated mutations in HIV-1 subtype C hyperacute infection.
HIV uninfected women at high risk for HIV infection were followed and sampled twice weekly as part of a comprehensive prevention and empowerment programme. Plasma samples from 14 participants, who were infected with HIV-1 during study follow-up, were obtained within one week of onset of plasma viremia (OPV) and at regular intervals thereafter and subject to ultra-deep pyrosequencing (454 Life Sciences, Roche Diagnostics). Data was analysed using the amplicon variant analyser where the cut-off for low frequency drug resistance mutations (DRMs) was 1%.
UDPS identified low frequency DRMs in 8 out of 14 participants (57%). The K65R nucleotide reverse transcriptase inhibitor (NRTI) associated DRM was the most prevalent low frequency DRM detected (6 out of 14 participants, 47%). Other DRMs detected included the D67N (3.88%) NRTI-associated DRM, the F53L (17.6%) and M46L (6.3%) protease inhibitor (PI) associated DRMs and the T97A integrase strand transfer inhibitor (InSti) associated DRM. The K103N NNRTI-associated DRM was detected in high frequency. Whilst the K103N DRM persisted at 1 year after OPV, the F53L and M46L DRMs reverted as early as 7 days after OPV.
Our results showed that low frequency mutations are common in HIV-1 subtype C hyperacute infection. Most of these mutations reverted rapidly and thus would be undetectable by routine methods used in the surveillance of TDR. The possible storage of TDR associated mutations in latent reservoirs raises concern for their reemergence under drug selection pressure and their subsequent impact on treatment outcomes. Further work to identify viral species in latent reservoirs is suggested for this cohort.